Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant Inc (IMVT) is a clinical-stage biopharmaceutical company pioneering FcRn inhibitor therapies for autoimmune diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory developments, and corporate milestones driving innovation in immunology.
Access authoritative information on batoclimab and IMVT-1402 clinical progress, partnership announcements, and financial disclosures. Our curated collection ensures you stay informed about key advancements in monoclonal antibody research without promotional bias.
Discover comprehensive updates including trial result analyses, FDA communications, and strategic initiatives shaping Immunovant's pipeline. The content is structured to serve both seasoned investors and those new to biopharma developments.
Bookmark this page for reliable, up-to-date information on Immunovant's scientific achievements and business trajectory. Check back regularly for verified news impacting the future of autoimmune disease treatments.
Immunovant (IMVT) reported progress in its clinical programs and financial results for Q1 FY2025 ended June 30, 2024. Key highlights include:
1. Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial
2. On track to initiate IMVT-1402 registrational program by March 31, 2025
3. Three IND applications for IMVT-1402 expected to be active by December 31, 2024
4. Cash position of $560 million as of June 30, 2024
5. R&D expenses increased to $75.5 million from $50.6 million YoY
6. Net loss of $87.2 million ($0.60 per share) compared to $73.9 million ($0.57 per share) YoY
The company aims to initiate 4-5 registrational programs for IMVT-1402 by March 2025 and clinical trials in 10 indications by March 2026.
Immunovant (Nasdaq: IMVT) reported corporate updates and financial results for the fourth quarter and fiscal year ended March 31, 2024.
The company plans to initiate 4-5 potentially registrational studies for its lead asset IMVT-1402 in various therapeutic areas by March 31, 2025. Topline data from the batoclimab Myasthenia Gravis study is expected in the same timeframe.
R&D expenses for Q4 increased to $66.1M, and net loss widened to $75.3M. For the fiscal year, R&D expenses rose to $212.9M, and net loss was $259.3M.
IMVT's cash position was approximately $635M as of March 31, 2024. They hold a new U.S. patent extending until June 2043.
FAQ
What is the current stock price of Immunovant (IMVT)?
What is the market cap of Immunovant (IMVT)?
